{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T20:30:18Z","timestamp":1772742618939,"version":"3.50.1"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>Treatment strategies for cutaneous squamous cell carcinoma in situ (cSCCIS) are many but reported cure rates are variable and few studies report 5-year follow-up data.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>To evaluate the treatment of cSCCIS by curettage followed by topical imiquimod 5% cream (C&amp;I).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>We evaluated all immunocompetent patients with biopsy proven cSCCIS treated by C&amp;I between January 2008 and December 2012.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>A total of 861 patients with 1,198 cSCCIS were treated, with median follow-up of 71 months. The mean tumor diameter was 10.2 mm. The average duration of treatment with imiquimod 5% cream was 21 days. Kaplan\u2013Meier estimated recurrence-free survival at 5-year follow-up was 99.71% with 95% CI (99.38%, 100.00%). A follow-up questionnaire returned by 45% of patients revealed that 94% were satisfied with their treatment. Six hundred eleven patients developed a new nonmelanoma skin cancer (NMSC) during the follow-up period, and 91% (556\/611) of patients chose this combination treatment for at least one new NMSC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>The combination treatment for cSCCIS of C&amp;I had less than 1% cumulative probability of treatment failure at 5 years. Patients tolerated the treatment well, with the majority choosing this method of treatment for at least one new NMSC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000002945","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T16:38:45Z","timestamp":1611247125000},"page":"609-612","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Treatment of Cutaneous Squamous Cell Carcinoma In Situ With Curettage Followed by Topical Imiquimod 5% Cream"],"prefix":"10.1097","volume":"47","author":[{"given":"Andrew L.","family":"Ondo","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of New Mexico School of Medicine, Albuquerque, New Mexico;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James D.","family":"Kerner","sequence":"additional","affiliation":[{"name":"Department of Health and Social Services, New Mexico State University, Las Cruces, New Mexico;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob V.","family":"Kerner","sequence":"additional","affiliation":[{"name":"Department of Molecular, Cellular and Developmental Biology, University of California at Santa Barbara, SantaBarbara, California;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaac P.","family":"Ondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Trainor","sequence":"additional","affiliation":[{"name":"Applied Statistics, New Mexico State University, Las Cruces, New Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart D.","family":"Shanler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,1,13]]},"reference":[{"key":"R1-20250731","first-page":"CD007281","article-title":"Interventions for cutaneous Bowen's disease","author":"Bath-Hextall","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"R2-20250731","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/bjd.12766","article-title":"British Association of Dermatologists' guidelines for the management of squamous cell carcinoma in situ (Bowen's disease) 2014","volume":"170","author":"Morton","year":"2014","journal-title":"Br J Dermatol"},{"key":"R3-20250731","first-page":"AB174","article-title":"Effectiveness of curettage and 5% imiquimod cream in the treatment of basal cell carcinoma: clinical and cosmetic evaluation","volume":"54","author":"Rigel","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"1 Suppl 1","key":"R4-20250731","first-page":"s15","article-title":"Imiquimod 5% cream following curettage without electrodessication for basal cell carcinoma: preliminary report","volume":"7","author":"Rigel","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"R7-20250731","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1084\/jem.20071190","article-title":"Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells","volume":"205","author":"Clark","year":"2008","journal-title":"J Exp Med"},{"key":"R8-20250731","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/bjd.14996","article-title":"Pretreatment with topical glucocorticoids to enhance the antitumour efficacy of imiquimod: long-term follow-up in Bowen disease","volume":"176","author":"Okazaki","year":"2017","journal-title":"Br J Dermatol"},{"key":"R9-20250731","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jaad.2004.12.033","article-title":"Cutaneous squamous cell carcinoma in situ (Bowen's disease): treatment with Mohs micrographic surgery","volume":"52","author":"Leibovitch","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"R10-20250731","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jaad.2015.09.060","article-title":"Histopathologic assessment of depth of follicular invasion of squamous cell carcinoma (SCC) in situ (SCCis): implications for treatment approach","volume":"74","author":"Christensen","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"R11-20250731","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jaad.2012.06.009","article-title":"AAD\/ACMS\/ASDSA\/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American academy of dermatology, American College of Mohs surgery, American society for dermatologic surgery association, and the American society for Mohs surgery","volume":"67","author":"Connolly","year":"2012","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000002945","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T22:15:57Z","timestamp":1754000157000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000002945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,13]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000002945","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,13]]}}}